This is a long-acting beta2-adrenergic agonist indicated for: The long term,once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Important limitations: ? It is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ? It is not indicated for asthma.
Long-acting selective β2-adrenoceptor stimulants
Caterol is a long-acting β2-adrenergic agonist indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Caterol is a long-acting β2-adrenergic agonist. When inhaled, Caterol acts locally in the lung as a bronchodilator. The pharmacological effects of β2-adrenoceptor agonist drugs, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’,5’-adenosine monophosphate (cyclic monophosphate). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle.
For oral inhalation only. Do not swallow this capsule. thiscapsules should always be used with the inhaler only. 75/150 mcg inhaled every day (once-daily).
Caterol shows interaction with Adrenergic Drugs, Xanthine Derivatives, Steroids, or Diuretics. Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of Caterol. The ECG changes or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β2-agonists. Caterol, as with other β2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs known to prolong the QTc interval. β-adrenergic receptor antagonists (beta-blockers) and Caterol may interfere with the effect of each other when administered concurrently.
All are contraindicated in patients with asthma without use of a longterm asthma control medication. It is not indicated for the treatment of asthma. ? It is contraindicated in patients with a history of hypersensitivity to indacaterol or to any of the ingredients.
Cough,oropharyngeal pain,nasopharyngitis,headache and nausea
Teratogenic Effects: Pregnancy Category C. There are no adequate and well-controlled studies with It in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Indacaterol was not teratogenic following subcutaneous administration to rats and rabbits at doses up to 1 mg/kg,approximately 130 and 260 times, respectively,the 75 mcg dose on a mg/m2 basis. It is not known that the active component of It, indacaterol,is excreted in human milk. Because many drugs are excreted in human milk and because indacaterol has been detected in the milk of lactating rats,caution should be exercised when It is administered to nursing women.
The expected signs and symptoms associated with over dosage of Caterol powder are those of excessive beta-adrenergic stimulation and occurrence or exaggeration of any of the signs and symptoms, e.g., angina, hypertension or hypotension, tachycardia, with rates up to 200 bpm, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, metabolic acidosis and insomnia. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an over dose of Caterol powder.
Caterol capsules must always be stored in the blister, and only removed immediately before use. Keep in a cool & dry place. Keep out of the reach of children.
.png&w=384&q=75)